FluoGuide: FG001 receives Fast Track designation - Redeye

Redeye is encouraged by FluoGuide receiving FDA Fast Track Designation for FG001 in High-Grade Glioma. This gives positive regulatory momentum ahead of the U.S. Phase 2 registration trial. We expect the share to trade up at least 15% today.

Länk till analysen i sin helhet: https://www.redeye.se/research/1157411/fluoguide-fg001-receives-fast-track-designation?utm_source=finwire&utm_medium=RSS